LIFE Stock Overview
Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries.
Public Joint-Stock Company "Pharmsynthez" Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₽4.51|
|52 Week High||₽7.00|
|52 Week Low||₽2.65|
|1 Month Change||0%|
|3 Month Change||10.15%|
|1 Year Change||-23.51%|
|3 Year Change||-0.77%|
|5 Year Change||-62.92%|
|Change since IPO||-81.14%|
Recent News & Updates
|LIFE||RU Pharmaceuticals||RU Market|
Return vs Industry: LIFE underperformed the Russian Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: LIFE exceeded the Russian Market which returned -38.9% over the past year.
|LIFE Average Weekly Movement||n/a|
|Pharmaceuticals Industry Average Movement||5.4%|
|Market Average Movement||5.6%|
|10% most volatile stocks in RU Market||10.4%|
|10% least volatile stocks in RU Market||2.9%|
Stable Share Price: Insufficient data to determine LIFE's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine LIFE's volatility change over the past year.
About the Company
Public Joint-Stock Company ‘Pharmsynthez’, a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company ‘Pharmsynthez’ has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia.
Public Joint-Stock Company "Pharmsynthez" Fundamentals Summary
|LIFE fundamental statistics|
Is LIFE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LIFE income statement (TTM)|
|Cost of Revenue||₽244.37m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.22|
|Net Profit Margin||-148.38%|
How did LIFE perform over the long term?See historical performance and comparison